+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Latin America Liver Cancer Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4763998
  • Report
  • March 2019
  • Region: Latin America
  • 65 pages
  • Mordor Intelligence
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Bayer AG
  • Eli Lilly And Co.
  • F Hoffmann-La Roche Ltd
  • GE Healthcare
  • Koninklijke Philips NV
  • Onyx Pharmaceuticals Inc.
  • MORE
Market Overview

The Latin American liver cancer market is expected to register a CAGR of nearly 7.4% during the forecast period.
  • Changes in the current lifestyle of individuals have led to the exposure of a large amount of population to the risk factors that contribute to liver cancer. The risk factors include hepatitis (caused by either the hepatitis B or hepatitis C virus), type-2 diabetes, metabolic disorders, excess body weight, alcohol consumption, and tobacco smoking. It has also been observed that liver cancer risk increases substantially with the increase in one’s body mass index (BMI).
  • According to the OECD Obesity Update 2017, obesity levels are particularly high in Latin American countries for example in Mexico, 32.4% of males aged 15 years and over are obese as of 2017, and nearly 39% of the population is projected to become obese by 2030.
Scope of the Report

The scope of the Latin American liver cancer market encompasses various diagnostic modalities used in the diagnosis and imaging of liver cancer and available therapies used in the management of liver cancer. Diagnostic modalities include ultrasound scans, biopsy, endoscopy, CT scan, PET scan, and magnetic resonance imaging (MRI) scans, among others. Therapeutic categories covered in the report include targeted therapy, radiation therapy, immunotherapy, and chemotherapy.

Key Market Trends

By Cancer Type Hepatocellular Carcinoma Hold the Largest Share

Hepatocellular carcinoma is the most common form of liver cancer, which mostly occurs in people suffering from chronic liver disease, like cirrhosis. Hepatocellular carcinoma is one of the major causes leading to cancer-related deaths, globally. It is observed that the developing countries of the Latin American region have higher incidence rates of hepatocellular carcinoma than the developed countries, due to the disparity in the major risk factors, such as hepatitis C virus (HCV) and hepatitis B virus (HBV) infections, causing hepatocellular carcinoma in those regions. With the increase in the incidence of hepatocellular carcinoma, liver cancer therapeutics is expected to have huge demand. Hence, the rising incidence of cancer and high unmet medical needs are the major factors driving the market in the forecast period.

Competitive Landscape

The Latin American liver cancer market is consolidated with some major players controlling the major share of the market, especially in the diagnostics space. Liver cancer diagnostics are majorly dependent on high-cost diagnostic imaging modalities, such as MRI, CT, and PET scanners. There are few major players in the global market, and due to the low volume of demand in Latin American countries, the concentration of medical device manufacturers is even lower. In the Latin American therapeutic space, several niche players operate and various clinical trials are underway.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bayer AG
  • Eli Lilly And Co.
  • F Hoffmann-La Roche Ltd
  • GE Healthcare
  • Koninklijke Philips NV
  • Onyx Pharmaceuticals Inc.
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidence of Cancer
4.2.2 High Unmet Medical Needs
4.3 Market Restraints
4.3.1 Adverse Effects of Drugs
4.3.2 High Cost of Therapeutics and Diagnostic Devices
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Cancer Type
5.1.1 Hepatocellular Carcinoma
5.1.2 Cholangiocarcinoma
5.1.3 Hepatoblastoma
5.2 By Modality
5.2.1 Diagnostics
5.2.1.1 Ultrasound Scans
5.2.1.2 Biopsy
5.2.1.3 Endoscopy
5.2.1.4 CT Scan
5.2.1.5 PET Scan
5.2.1.6 Magnetic Resonance Imaging (MRI) Scans
5.2.2 Therapeutics
5.2.2.1 Targeted Therapy
5.2.2.2 Radiation Therapy
5.2.2.3 Immunotherapy
5.2.2.4 Chemotherapy
5.3 Geography
5.3.1 Latin America
5.3.1.1 Mexico
5.3.1.2 Brazil
5.3.1.3 Argentina
5.3.1.4 Rest of Latin America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Alnylam Pharmaceuticals Inc.
6.1.2 Bayer AG
6.1.3 Bristol-Myers Squibb Company
6.1.4 Eli Lilly And Co.
6.1.5 F Hoffmann-La Roche Ltd
6.1.6 GE Healthcare
6.1.7 Koninklijke Philips NV
6.1.8 Onyx Pharmaceuticals Inc.
6.1.9 Pfizer Inc.
6.1.10 Siemens Healthineers

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Alnylam Pharmaceuticals Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly And Co.
  • F Hoffmann-La Roche Ltd
  • GE Healthcare
  • Koninklijke Philips NV
  • Onyx Pharmaceuticals Inc.
  • Pfizer Inc.
  • Siemens Healthineers
Note: Product cover images may vary from those shown
Adroll
adroll